MIVACURIUM HYDROXIDE

Details

Stereochemistry	MIXED
Molecular Formula	C58H80N2O14.2HO
Molecular Weight	1063.2755
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].COC1=CC2=C(C=C1OC)[C@@H](CC3=CC(OC)=C(OC)C(OC)=C3)[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]4(C)CCC5=CC(OC)=C(OC)C=C5[C@@H]4CC6=CC(OC)=C(OC)C(OC)=C6)CC2

InChI

InChIKey=FXHLWQXSTCTSDZ-VBBWHNEHSA-L

InChI=1S/C58H80N2O14.2H2O/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10;;/h13-14,31-38,45-46H,15-30H2,1-12H3;2*1H2/q+2;;/p-2/b14-13+;;/t45-,46+,59?,60?;;

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C58H80N2O14
Molecular Weight	1029.2608
Charge	2
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	2 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1373287 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078562s000lbl.pdf

Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscle-type nicotinic acetylcholine receptor 65 Target ID: CHEMBL2362997 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078562s000lbl.pdf \| http://drugcentral.org/drugcard/1822?q=MIVACURIUM \| https://www.ncbi.nlm.nih.gov/pubmed/19417616	Antagonist 2849		3.69 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Muscle relaxation 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078562s000lbl.pdf	Primary		Approved 8583	MIVACRON Approved Use MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date 1992

C_max

Value	Dose	Analyte	Population
4486 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, TRANS-TRANS- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2198 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-TRANS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
504 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-CIS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
2.932 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, TRANS-TRANS- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.178 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-TRANS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.295 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-CIS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, TRANS-TRANS- plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-TRANS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28.5 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/	0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	MIVACURIUM, CIS-CIS- plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.2 mg/kg single, intravenous Recommended Dose: 0.2 mg/kg Route: intravenous Route: single Dose: 0.2 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf	Other AEs: Anaphylactic reaction... Other AEs: Anaphylactic reaction (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf

AEs

AE	Significance	Dose	Population
Anaphylactic reaction	grade 3-5	0.2 mg/kg single, intravenous Recommended Dose: 0.2 mg/kg Route: intravenous Route: single Dose: 0.2 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1NQXXZ
AN PharmaTech	AN-33846
BOC Sciences	106791-40-6	https://www.bocsci.com/mivacurium-cas-106791-40-6-item-81392.html
ChemMol	49421596	http://www.chemmol.com/chemmol/49421596.html
eNovation Chemicals	D674576	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674576
MuseChem	M012797	https://www.musechem.com/product/M012797.html
MuseChem	M130592	https://www.musechem.com/product/M130592.html
NovoSeek	5281042
OChem	22912	http://www.ocheminc.com/index.php?act=psearch&pid=791M406
PubChem	5281042	https://pubchem.ncbi.nlm.nih.gov/compound/5281042

PubMed

Title	Date	PubMed
Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.	2014	25054547
Fresh frozen plasma transfusion for reversal of prolonged post-anaesthesia apnoea.	2008-04	18399847
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.	2006-09	16931985
Unexpected prolonged paralysis after mivacurium in a patient with Bamforth syndrome.	2006-08	16884476
Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India.	2006-07	16788378
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials.	2005-10	16192781
Prolonged paralysis related to mivacurium: a case study.	2005-02	15688329
The cardiovascular effects of mivacurium in hypertensive patients.	2002-08	12145055
[Plasma cholinesterase variations as a result of prolonged neuromuscular blockade. Review and problems encountered in two cases of prolonged neuromuscular blockade after muscle relaxation with succinylcholine as compared to mivacurium].	2002-02	11963306
Is succinylcholine after pretreatment with d-tubocurarine and lidocaine contraindicated for outpatient anesthesia?	2000-08	10910840
Intubation conditions and postoperative myalgia in outpatient dental surgery: a comparison of succinylcholine with mivacurium.	2000-04	10788964
Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes.	2000-02	10648343
Organophosphorus pesticide-induced butyrylcholinesterase inhibition and potentiation of succinylcholine toxicity in mice.	1999	9890196
Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency.	1998-11	10023281
The effect of mivacurium pretreatment on intra-ocular pressure changes induced by suxamethonium.	1998-05	9659028
Potentiation of mivacurium by rocuronium is age- and time-dependent: a study in children, adolescents, and young and elderly adults.	1997-07	9243359
Markedly prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing.	1997-02	9024049
Clinical pharmacology of mivacurium chloride: a review.	1992-03-01	1373287

Patents

Sample Use Guides

In Vivo Use Guide

Adults Initial Doses Doses of 0.15 mg/kg administered over 5 to 15 seconds, 0.20 mg/kg administered over 30 seconds, or 0.25 mg/kg administered in divided doses (0.15 mg/kg followed in 30 seconds by 0.10 mg/kg) are recommended for facilitation of tracheal intubation for most patients

Route of Administration: Intravenous

In Vitro Use Guide

The left or right atria of rats were removed and suspended in organ baths. Mivacurium was added cumulatively (10(-9)-10(-5) M) in the presence and absence of the nonselective β-blocker propranolol (10(-8) M) and the noradrenaline reuptake inhibitor desipramine (10(-7) M), and heart rate changes were recorded in spontaneously beating right atria. Mivacurium increased developed force in a dose-dependent manner; the increases were significant at 10(-5) M concentration for mivacurium.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:02:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:02:46 GMT 2025`
Record UNII	FM8VA7ORPP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ISOQUINOLINIUM, 2,2'-(((4E)-1,8-DIOXO-4-OCTENE-1,8-DIYL)BIS(OXY-3,1-PROPANEDIYL))BIS(1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-((3,4,5-TRIMETHOXYPHENYL)METHYL)-, HYDROXIDE (1:2), (1R,1'R)-

Preferred Name

English

MIVACURIUM HYDROXIDE

Common Name

English

Code System Code Type Description

PUBCHEM

135390842

Created by admin on Mon Mar 31 18:02:46 GMT 2025 , Edited by admin on Mon Mar 31 18:02:46 GMT 2025

PRIMARY

FDA UNII

FM8VA7ORPP

Created by admin on Mon Mar 31 18:02:46 GMT 2025 , Edited by admin on Mon Mar 31 18:02:46 GMT 2025

PRIMARY

Related Record Type Details


					77D66S9Q93

MIVACURIUM

ACTIVE MOIETY